An anonymous director reports

ZYUS LIFE SCIENCES PROVIDES AN UPDATE ON ITS UNIT OFFERING

Zyus Life Sciences Corp. has provided an update on its previously announced non-brokered private placement. As disclosed in the company's news release dated March 20, 2026, Zyus raised a total of $284,300 in gross proceeds in the first tranche of the offering, which closed on March 20, 2026. The company confirms that no additional tranches were completed, no additional proceeds were received and no further securities will be issued under the offering. The company continues to evaluate additional financing opportunities as needed. The company has drawn down on its revolving credit facility to meet its working capital requirements.

About Zyus Life Sciences Corp.

Zyus is a clinical-stage life science company focused on the development and commercialization of novel non-opioid pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, Zyus aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. Zyus's unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions in pursuit of transformational impact on patients' lives.

We seek Safe Harbor.